CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Translation adjustment	$ (20,205,000)			$ (20,205,000)
Balance at Dec. 31, 2021	1,750,067,000	$ 553,000	$ 1,572,340,000	(16,886,000)	$ 194,060,000
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net Income (Loss)	96,825,000				96,825,000
Issuance of common stock for debt conversion	(5,000)	$ 0	(5,000)
Issuance of common stock for debt conversion (in shares)		12
Exercise of stock options and vesting of stock units	463,000	$ 3,000	460,000
Exercise of stock options and vesting of stock units (in shares)		222,727
Tax withholding on vesting of restricted stock units	(14,759,000)	$ (1,000)	(14,758,000)
Tax withholding on vesting of restricted stock units (in shares)		(78,278)
Stock-based compensation expense	14,900,000		14,900,000
Other	(105,000)		(105,000)
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Jun. 30, 2022		55,465,918
Translation adjustment	(15,517,000)			(15,517,000)
Balance at Mar. 31, 2022	1,766,401,000	$ 554,000	1,529,144,000	(21,574,000)	258,277,000
Beginning Balance (in shares) at Mar. 31, 2022		55,429,046
Net Income (Loss)	49,861,000				49,861,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		4
Exercise of stock options and vesting of stock units	166,000	$ 1,000	166,000
Exercise of stock options and vesting of stock units (in shares)		51,737
Tax withholding on vesting of restricted stock units	(2,448,000)	$ 0	(2,448,000)
Tax withholding on vesting of restricted stock units (in shares)		(14,869)
Stock-based compensation expense	6,985,000		6,985,000
Other	(82,000)		(82,000)
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Balance (Accounting Standards Update 2020-06 [Member]) at Jun. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Jun. 30, 2022		55,465,918
Translation adjustment	(2,795,000)			(2,795,000)
Balance at Dec. 31, 2022	1,910,700,000	$ 556,000	1,547,266,000	(34,394,000)	397,272,000
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net Income (Loss)	48,893,000				48,893,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	62,000	$ 2,000	60,000
Exercise of stock options and vesting of stock units (in shares)		176,394
Tax withholding on vesting of restricted stock units	(11,140,000)	$ (1,000)	(11,139,000)
Tax withholding on vesting of restricted stock units (in shares)		(63,238)
Issuance of commons stock pursuant to the acquisition	5,243,000	$ 0	5,243,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000	$ 0	7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		42,621
Stock-based compensation expense	12,737,000		12,737,000
Balance at Jun. 30, 2023	1,970,926,000	$ 557,000	1,561,393,000	(37,189,000)	446,165,000
Ending Balance (in shares) at Jun. 30, 2023		55,744,896
Translation adjustment	(6,068,000)			(6,068,000)
Balance at Mar. 31, 2023	1,940,492,000	$ 556,000	1,544,956,000	(31,121,000)	426,101,000
Beginning Balance (in shares) at Mar. 31, 2023		55,644,301
Net Income (Loss)	20,064,000				20,064,000
Issuance of common stock for debt conversion	(3,000)	$ 0	(3,000)
Issuance of common stock for debt conversion (in shares)		6
Exercise of stock options and vesting of stock units	33,000	$ 1,000	32,000
Exercise of stock options and vesting of stock units (in shares)		36,184
Tax withholding on vesting of restricted stock units	(1,547,000)	$ 0	(1,547,000)
Tax withholding on vesting of restricted stock units (in shares)		(9,631)
Issuance of commons stock pursuant to the acquisition	5,243,000	$ 0	5,243,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000	$ 0	7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		42,621
Stock-based compensation expense	5,483,000		5,483,000
Balance at Jun. 30, 2023	$ 1,970,926,000	$ 557,000	$ 1,561,393,000	$ (37,189,000)	$ 446,165,000
Ending Balance (in shares) at Jun. 30, 2023		55,744,896